In just five trading days, the share price fell by more than 50%, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) can be called the “nightmare” of investors in 2022.
shares fell for five consecutive days, halving
29.4 yuan temporarily became the highest price in Jiangxi Fushine Pharmaceutical Co.Ltd(300497) 2022. After peaking, the stock continued to decline in the following trading days. In just five trading days, , the stock fell by more than 55% . As of today’s close, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) share price hit a new low in nearly five months.
The type a trend of stock price made many investors call “reversal” too fast. Just the day before the stock price hit a record high, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) had a strong limit, and opened with a “posture” of one word limit on the day after the limit. It was this strong opening that buried the root of the “collapse” of stock price.
On January 20, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) in the case of the previous day’s limit, the opening of the price limit with one word, the bidding traded 339 million yuan , and the fund-raising is still fierce. But the 20% increase, even for investors who played the board the day before, was also an “instant” explosion. The lucrative funds swarmed out after the opening, but the relay funds were insufficient. After Jiangxi Fushine Pharmaceutical Co.Ltd(300497) fried the board, the stock price fell step by step, opened higher and lower all day, and finally fell sharply by 7%. The transaction amount also set a historical record of 5 billion yuan .
In addition, it is worth mentioning that the collapse of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) share price is also the epitome of the trend of “anti epidemic concept stocks”. Both covid-19 detection and covid-19 drug concept stocks have fallen sharply since January 20. In addition, the recent performance of the whole market is also quite depressed, which means that the market has hardly given the stock the opportunity to “save itself”.
big men lose their halberds and retail investors lose money
The share price has tumbled down from the historical high price of 29.4 yuan, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) is a “nightmare” for investors involved. Even for investors trying to copy the bottom, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) ‘s five consecutive declines did not give people a chance to “make money” to leave the market. in the process of this round of killing and falling, both big men and retail investors lost a mess .
On January 20 and January 21, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) boarded the dragon and tiger list twice. Combined with the data of the two dragon and tiger lists, we can clearly see the tragic “defeat” of the big man. On January 20, Zhejiang branch of Shengang securities spent 113 million yuan to buy the stock, ranking the top of the dragon and tiger list at that time. In addition, well-known business departments such as Hangzhou West Lake International Trade Center Business Department of Caixin securities and Everbright Securities Company Limited(601788) Ningbo Jiefang South Road business department all spent tens of millions to buy the stock.
However, on that day, the stock almost received the “enema Yin” trend, which means that almost all investors who bought the stock on that day lost money, and the short jump and low opening on the next day made it difficult for investors who bought at how low a price the previous day to escape the fate of being “killed”, and Shengang securities Zhejiang branch was not spared.
On January 21, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) was once again on the dragon and tiger list. The data showed that the Zhejiang branch of Shengang securities, which had bought 113 million shares of the stock the previous day, sold only 76 million yuan, which means that the Zhejiang branch of Shengang securities lost 37 million yuan in two trading days, accounting for nearly 33%.
It is worth mentioning that retail investors are the biggest victims in this “accident scene”. According to the data disclosed by the Shenzhen Stock Exchange, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) fell by 46% from January 20 to January 26. During the period of serious abnormal decline, natural persons bought a total of 10.157 billion yuan, accounting for 86.59% ; Among them, small and medium-sized investors bought 4.994 billion yuan, accounting for 42.57%. Institutions bought a total of 1.305 billion yuan, accounting for 11.12%.
